Cargando…

Radiolysis-Associated Decrease in Radiochemical Purity of (177)Lu-Radiopharmaceuticals and Comparison of the Effectiveness of Selected Quenchers against This Process

The radiolytic degradation of vector molecules is a major factor affecting the shelf life of therapeutic radiopharmaceuticals. The development of time-stable dosage forms of radiopharmaceuticals is the key to their successful implementation in clinical practice. Using [(177)Lu]Lu-PSMA-617 molecule a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Larenkov, Anton, Mitrofanov, Iurii, Pavlenko, Ekaterina, Rakhimov, Marat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967390/ https://www.ncbi.nlm.nih.gov/pubmed/36838872 http://dx.doi.org/10.3390/molecules28041884

Ejemplares similares

Preparation of Zirconium-89 Solutions for Radiopharmaceutical Purposes: Interrelation Between Formulation, Radiochemical Purity, Stability and Biodistribution
por: Larenkov, Anton, et al.
Publicado: (2019)

Development and Validation of Analytical Methods for Radiochemical Purity of (177)Lu-PSMA-1
por: Orhon, Pauline, et al.
Publicado: (2022)

Influence of DOTA Chelators on Radiochemical Purity and Biodistribution of (177)Lu- and (90)Y-Rituximab in Xenografted Mice
por: Karczmarczyk, Urszula, et al.
Publicado: (2018)

The determination of the radiochemical purity of Actinium-225 radiopharmaceuticals: a conundrum
por: Kleynhans, Janke, et al.
Publicado: (2022)

Influence of Storage Temperature on Radiochemical Purity of (99m)Tc-Radiopharmaceuticals
por: Uccelli, Licia, et al.
Publicado: (2018)

A suitable time point for quantifying the radiochemical purity of (225)Ac-labeled radiopharmaceuticals
por: Kelly, James M., et al.
Publicado: (2021)

Developments in (177)Lu-based radiopharmaceutical therapy and dosimetry
por: George, Siju C., et al.
Publicado: (2023)

Evaluation of the (177m)Lu-concentration in in-house produced (177)Lu-radiopharmaceuticals and commercially available Lutathera(®)
por: Balzer, Matthias, et al.
Publicado: (2023)

Quality control on radiochemical purity in Technetium-99m radiopharmaceuticals labelling: three years of experience on 2280 procedures
por: Maioli, Claudio, et al.
Publicado: (2017)

AAZTA(5)/AAZTA(5)-TOC: synthesis and radiochemical evaluation with (68)Ga, (44)Sc and (177)Lu
por: Sinnes, Jean-Philippe, et al.
Publicado: (2019)

Toxicity Assessment of [(177)Lu]Lu−iFAP/iPSMA Nanoparticles Prepared under GMP-Compliant Radiopharmaceutical Processes
por: Hernández-Jiménez, Tania, et al.
Publicado: (2022)

An alternative methodology for the determination of the radiochemical purity of (11)C-methionine
por: Giglio, Javier, et al.
Publicado: (2018)

Radiochemical and analytical aspects of inter-institutional quality control measurements on radiopharmaceuticals
por: de Blois, Erik, et al.
Publicado: (2019)

Estimation of relative biological effectiveness of (225)Ac compared to (177)Lu during [(225)Ac]Ac-PSMA and [(177)Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS
por: Rumiantcev, Mikhail, et al.
Publicado: (2023)

Targeted scVEGF/(177)Lu radiopharmaceutical inhibits growth of metastases and can be effectively combined with chemotherapy
por: Rusckowski, Mary, et al.
Publicado: (2016)

Impact of radiopharmaceutical therapy ((177)Lu, (225)Ac) microdistribution in a cancer-associated fibroblasts model
por: Tranel, Jonathan, et al.
Publicado: (2022)

Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021)

Radiolabeling and quality control of therapeutic radiopharmaceuticals: optimization, clinical implementation and comparison of radio-TLC/HPLC analysis, demonstrated by [(177)Lu]Lu-PSMA
por: Hooijman, Eline L., et al.
Publicado: (2022)

Targeted Auger electron-emitter therapy: Radiochemical approaches for thallium-201 radiopharmaceuticals
por: Rigby, Alex, et al.
Publicado: (2021)

Impact of the dead-time correction method on quantitative (177)Lu-SPECT (QSPECT) and dosimetry during radiopharmaceutical therapy
por: Desy, Alessandro, et al.
Publicado: (2022)

Synthesis and Ready to Use Kit Formulation of EDTMP for the Preparation of 177Lu-EDTMP as a Bone Palliation Radiopharmaceutical
por: Mercanoglu, Guldem, et al.
Publicado: (2023)

Accuracy of two dosimetry software programs for (177)Lu radiopharmaceutical therapy using voxel-based patient-specific phantoms
por: Ramonaheng, Keamogetswe, et al.
Publicado: (2022)

Pharmacokinetic Properties of (68)Ga-labelled Folic Acid Conjugates: Improvement Using HEHE Tag
por: Larenkov, Anton, et al.
Publicado: (2020)

Validation of the HPLC Analytical Method for the Determination of Chemical and Radiochemical Purity of Ga-68-DOTATATE
por: Sammartano, Antonino, et al.
Publicado: (2023)

Practical kidney dosimetry in peptide receptor radionuclide therapy using [(177)Lu]Lu-DOTATOC and [(177)Lu]Lu-DOTATATE with focus on uncertainty estimates
por: Staanum, Peter Frøhlich, et al.
Publicado: (2021)

First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2)
por: Ballal, Sanjana, et al.
Publicado: (2021)

Matched-pair analysis of [(177)Lu]Lu-PSMA I&T and [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Kidney absorbed radiation doses for [(177)Lu]Lu-PSMA-617 and [(177)Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry
por: Uijen, Maike J.M., et al.
Publicado: (2023)

Influence of sampling schedules on [(177)Lu]Lu-PSMA dosimetry
por: Rinscheid, Andreas, et al.
Publicado: (2020)

Extravasation of [(177)Lu]Lu-DOTATOC: case report and discussion
por: Arveschoug, Anne Kirstine, et al.
Publicado: (2020)

Improved quality control of [(177)Lu]Lu-PSMA I&T
por: Kraihammer, Martin, et al.
Publicado: (2023)

Urinary excretion kinetics of [(177)Lu]Lu-PSMA-617
por: de Bakker, Maarten, et al.
Publicado: (2023)

An investigation of aspects of radiochemical purity of (99m)Tc-labelled human serum albumin nanocolloid
por: Cusnir, Ruslan, et al.
Publicado: (2021)

Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals
por: Ladrière, Typhanie, et al.
Publicado: (2023)

Absorbed dose assessment of (177)Lu-zoledronate and (177)Lu-EDTMP for human based on biodistribution data in rats
por: Yousefnia, Hassan, et al.
Publicado: (2015)

Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [(177)Lu]Lu-OPS201 Compared to the Agonist [(177)Lu]Lu-DOTA-TATE
por: Mansi, Rosalba, et al.
Publicado: (2021)

Investigation of the Effect on the Albumin Binding Moiety for the Pharmacokinetic Properties of (68)Ga-, (205/206)Bi-, and (177)Lu-Labeled NAPamide-Based Radiopharmaceuticals
por: Szücs, Dániel, et al.
Publicado: (2023)

Radionuclide generator-based production of therapeutic (177)Lu from its long-lived isomer (177m)Lu
por: Bhardwaj, Rupali, et al.
Publicado: (2019)

Radiolysis of water
por: Van de Voorde, M.H.
Publicado: (1966)

Lutetium-177 DOTATATE Production with an Automated Radiopharmaceutical Synthesis System
por: Aslani, Alireza, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_bhr7776kk2tovlqslm1tgm0v0p